TGFBI corneal dystrophy is a group of genetic eye disorders caused by mutations in the TGFBI gene, resulting in abnormal ...

Future Market Insights (FMI) has unveiled a compelling new report forecasting significant expansion in the global fuchs endothelial corneal dystrophy market. The report highlights a surge in market ...

GenEditBio has dosed the first subject in an investigator-initiated trial of its in vivo genome editing programme, GEB-101, ...

This trial marks the world's first clinical study of an in vivo CRISPR-Cas ribonucleoprotein (RNP)-based genome editing investigational therapy for TGFBI corneal dystrophy. "Today, on National ...

The IIT of GEB-101 is an open-label and dose-escalation clinical study to investigate the tolerability of GEB-101 when combined with standard treatment phototherapeutic keratectomy in adults with ...